Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Prolong Pharmaceuticals logo — Innovative biopharmaceutical products to address critical he...

Prolong Pharmaceuticals

Innovative biopharmaceutical products to address critical health conditions and specialized manufacturing solutions for the pharmaceutical industry.

Founded 2005 United States South Plainfield, United States 22 employees Series Unknown Total: $30.00M Biopharma, Biotechnology +1

General Information

Company Name Prolong Pharmaceuticals
Founded Year 2005
Location United States South Plainfield, United States +1
Employees 22
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when Prolong Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Prolong Pharmaceuticals

Prolong Pharmaceuticals is a biopharmaceutical company established in 2005 and headquartered in New Jersey, United States. The company's slogan is to provide innovative biopharmaceutical products addressing critical health conditions and specialized manufacturing solutions for the pharmaceutical industry. Prolong Pharmaceuticals is focused on developing and marketing a range of biopharmaceutical products, including PEG-uricase for hyperuricemia treatment, PEG-arginase for addressing melanoma and hepatocellular carcinoma, PEG-protein for managing hypovolemic shock, PEG-peptide antibiotic for staphylococcus infections, and PEG-streptokinase for myocardial infarctions. They also offer anti-cancer agents and Erythropoietin for treating anemia. Additionally, the company provides custom manufacturing services and licenses its products to pharmaceutical companies. The most recent significant investment in Prolong Pharmaceuticals was a $30.00M Venture Round investment on 14 October 2010. The details of the investors involved in this round are not available at this time. Prolong Pharmaceuticals operates in the Biopharma, Biotechnology, and Pharmaceutical industries, aiming to offer solutions to critical health conditions through its diverse product portfolio and custom manufacturing services. With its focus on innovation and addressing unmet medical needs, Prolong Pharmaceuticals presents itself as a promising prospect for venture capital investment within the pharmaceutical sector.

Taxonomy: biopharmaceuticals, PEG-uricase, PEG-arginase, PEG-protein, PEG-peptide, PEG-streptokinase, bio-manufacturing, pharmaceutical industry, hyperuricemia treatment, cancer treatment, custom manufacturing, licensing, New Jersey, Erythropoietin

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 14 Oct 2010
Seed Round •••••• 1
Investor
01 Jan 2009

Prolong Pharmaceuticals Alternatives & Competitors

Prolong Pharmaceuticals vs
Acetylon Pharmaceuticals, Inc.
Acetylon Pharmaceuticals, Inc.

Acetylon Pharmaceuticals is pursuing development of next-generation, selective histone deacetylase (...

Private Equity
3 employees
Biotechnology, Health Care
Prolong Pharmaceuticals vs
Emmaus Life Sciences, Inc
Emmaus Life Sciences, Inc United States

Improving the lives of people with rare disease.

Seed
36 employees
Biopharma, Biotechnology
Prolong Pharmaceuticals vs
Tract Bio
Tract Bio United States

Discovering and developing novel therapies to transform the treatment of cancer and inflammatory dis...

2 employees
Health and Wellness, Life Sciences

FAQ About Prolong Pharmaceuticals

Innovative biopharmaceutical products to address critical health conditions and specialized manufacturing solutions for the pharmaceutical industry.
Prolong Pharmaceuticals was founded in 2005.
Prolong Pharmaceuticals is headquartered in South Plainfield, United States.
Prolong Pharmaceuticals operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Prolong Pharmaceuticals has approximately 22 employees.
Prolong Pharmaceuticals has completed 2 funding rounds, raising a total of $30.00M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Prolong Pharmaceuticals include Acetylon Pharmaceuticals, Inc., Emmaus Life Sciences, Inc, Tract Bio, BioLineRx, Aruvant. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Prolong Pharmaceuticals and Acetylon Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Prolong Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy